Cost Effectiveness Analysis Of Tenofovir Disoproxil Fumarate (Viread®) In The Treatment Of Patients With Chronic Hepatitis B (Chb) In Mexico

Abstract

Twelve-month time horizon was developed. Cost data specific for the Polish health care system was based on retrospective medical record review of patients with ulcerative colitis. Resource use associated with the surgery was based on clinical expert opinion. The unit costs of treatment were derived from Polish official tariff lists for health care services paid by public payer. Average body weight of the patient (60 kg) was based on data from registry of patients with Crohn's disease, assuming the similar nature of the disease. RESULTS: Infliximab was associated with a gain of 0.21 quality adjusted life years (QALYs) compared with colectomy. Additional costs associated with the biological treatment were estimated at 14,793 PLN. Incremental cost-utility ratio was estimated at 69,984 PLN/QALY for infliximab compared with colectomy. The sensitivity analysis showed a relative consistency of results. CONCLUSIONS: The estimated cost per QALY is much below official threshold (99,543 PLN/QALY) which indicates that treatment with infliximab is cost effective compared with surgical treatment in Polish conditions.